Skip to content

Category: clinical trial

MeiraGTx Treats First Patient in XLRP Gene-Therapy Trial

Source: Foundation Fighting Blindness Blog – Eye on the Cure – MeiraGTx Treats First Patient in XLRP Gene-Therapy Trial MeiraGTx, a gene-therapy company in London and New York City, has treated its first patient in a gene-therapy clinical trial for people with X-linked retinitis pigmentosa (XLRP) caused by mutations…

Email this to someoneTweet about this on TwitterShare on FacebookShare on Google+Pin on Pinterest

Twelve People Receive XLRS Gene Therapy in AGTC’s Clinical Trial

Source: Foundation Fighting Blindness Blog – Eye on the Cure – Twelve People Receive XLRS Gene Therapy in AGTC’s Clinical Trial Applied Genetics Technology Corporation (AGTC) reported that its gene therapy for X-linked retinoschisis (XLRS) has performed encouragingly in a Phase I/II, safety-oriented clinical trial taking place at seven…

Email this to someoneTweet about this on TwitterShare on FacebookShare on Google+Pin on Pinterest

SparingVision Formed to Advance Sight-Saving Protein for RP

Source: Foundation Fighting Blindness Blog – Eye on the Cure – SparingVision Formed to Advance Sight-Saving Protein for RP L to R: Florence Allouche Ghrenassia, PharmD, President, SparingVision; Frédérique Vidal, French Minister of Higher Education, Research and Innovation; José-Alain Sahel, MD, Co-Founder, SparingVision and Fondation Voir & Entendre; David…

Email this to someoneTweet about this on TwitterShare on FacebookShare on Google+Pin on Pinterest

Valproic Acid’s Effect Too Small in One-Year Clinical Trial

Source: Foundation Fighting Blindness Blog – Eye on the Cure – Valproic Acid’s Effect Too Small in One-Year Clinical Trial However, researchers identify a potentially powerful endpoint for evaluating emerging therapies in future studies. Results from a clinical trial sponsored by the Foundation Fighting Blindness Clinical Research Institute (FFB-CRI)…

Email this to someoneTweet about this on TwitterShare on FacebookShare on Google+Pin on Pinterest

Clinical Trial Authorized in the U.S. for Emerging LCA 10 Therapy

Source: Foundation Fighting Blindness Blog – Eye on the Cure – Clinical Trial Authorized in the U.S. for Emerging LCA 10 Therapy ProQR, a biotechnology company in the Netherlands, has received authorization from the U.S. Food and Drug Administration to start a Phase I/II clinical trial for its therapy…

Email this to someoneTweet about this on TwitterShare on FacebookShare on Google+Pin on Pinterest